HomeNewsBusinessCompaniesCOVID-19 impact: As AGMs go virtual, shareholders worry about management controls

COVID-19 impact: As AGMs go virtual, shareholders worry about management controls

Infosys and TCS to have their AGM June 27 and June 11 respectively, others like Wipro and HCL are expected to follow suit

May 30, 2020 / 16:29 IST
Story continues below Advertisement

Come fourth Saturday in June, huge auditorium in Christ University, Bengaluru will be abuzz. Not with students. But with close to 500 Infosys shareholders for the company’s annual general meeting (AGM).

However, 2020 will be different. For the first time, the company’s 39th AGM will go virtual thanks to COVID-19.

Story continues below Advertisement

In a Bombay Stock Exchange filing, the company said, “This is to inform that the 39th Annual General Meeting (AGM) of the Company will be held over video conference on Saturday, June 27, 2020.”

Infosys is not the only firm to take the virtual route for AGM at the back of the virus outbreak. TCS too is taking its 25th AGM virtual on June 11 at 3.30 PM. Though Wipro and HCL Tech are yet to announce the dates, they too are likely to go virtual.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show